Page last updated: 2024-11-01

nimodipine and Neurodegenerative Diseases

nimodipine has been researched along with Neurodegenerative Diseases in 3 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.

Research Excerpts

Excerpt	Relevance	Reference
" The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-γ."	1.38	Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. ( Hashioka, S; Klegeris, A; McGeer, PL, 2012)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Yan, J	1
Huang, Y	1
Lu, Y	1
Chen, J	1
Jiang, H	1
Hashioka, S	1
Klegeris, A	1
McGeer, PL	1
Choudhary, S	1
Verma, SK	1
Raheja, G	1
Kaur, P	1
Joshi, K	1
Gill, KD	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]				29 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Evidence that the dose is insufficient.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Diastolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-0.6
Control	1

Heart Rate

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.

Intervention	beats per minute (Mean)
Treatment	-1.4
Control	4

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-1.3
Control	-0.25

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Intervention	units on a scale (Mean)
Treatment	12.5
Control	17.7

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-44.03
Control	-6.07

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-27.3
Control	0.4

Systolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-4.5
Control	-6.6

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	64.3	35.0	90.0	16.7

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	31.8	24.14	72.00	8.00

Other Studies

3 other studies available for nimodipine and Neurodegenerative Diseases

Article	Year
Repeated administration of ketamine can induce hippocampal neurodegeneration and long-term cognitive impairment via the ROS/HIF-1α pathway in developing rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2014, Volume: 33, Issue:6 Topics: Analgesics; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calcium Channel Blockers; Carni	2014
Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology, 2012, Volume: 63, Issue:4 Topics: Astrocytes; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Cells, Cultured; Chemokin	2012
The L-type calcium channel blocker nimodipine mitigates cytoskeletal proteins phosphorylation in dichlorvos-induced delayed neurotoxicity in rats. Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:5 Topics: Animals; Brain; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium-Calmodulin-Dependent Pro	2006